You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK):中國醫藥保健品成為公司利托那韋片在中國大陸的經銷商

格隆匯4月13日丨歌禮制藥-B(01672.HK)發佈公吿,歌禮藥業(浙江)有限公司與中國醫藥保健品有限公司已簽署經銷商協議,中國醫藥保健品有限公司成為歌禮藥業利托那韋片在中國大陸地區的經銷商。歌禮藥業是公司全資附屬公司,中國醫藥保健品有限公司是中國醫藥健康產業股份有限公司(上海證券交易所股份代號:600056)的全資附屬公司。

利托那韋片是多種針對病毒蛋白酶的口服抗病毒藥物的藥代動力學增強劑。歌禮擁有目前中國唯一通過生物等效性研究獲批上市的利托那韋口服片。歌禮利托那韋口服片於2021年9月獲中國國家藥品監督管理局批准上市(藥品批准文號:國藥準字H20213698)。

歌禮已向12個歐洲國家(德國、法國、愛爾蘭、英國、西班牙、葡萄牙、意大利、比利時、波蘭、瑞典、荷蘭和丹麥)和中國香港遞交了利托那韋(100毫克薄膜衣片)上市許可申請。

中國醫藥董事長、黨委書記李亞東表示:“中國醫藥作為醫藥行業國家隊,始終踐行守護人民健康初心使命,希望以此為契機探索與以歌禮為代表的中國創新藥企業的多層面合作,共同助力實現健康中國2030的宏偉目標”。

歌禮創始人、董事會主席兼首席執行官吳勁梓博士表示:“非常榮幸與中國醫藥達成商業化合作。中國醫藥是國內領先的藥品分銷商,擁有覆蓋全國的抗病毒藥物銷售終端網絡。歌禮抗病毒管線已上市產品包括中國唯一通過生物等效性試驗獲批上市的利托那韋片。公司期待與中國醫藥攜手合作,雙方依託各自產品與資源優勢,共同為消除傳染性疾病盡企業的社會責任”。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account